Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

process development for TB-403 production. ThromboGenics received EUR3 million of the overall EUR5 million success fee.

Corporate Update

ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at the Scrip Awards 2009

    - In September 2009, ThromboGenics was shortlisted for "Biotech
      Company of the Year" and "Licensing Deal of the Year" at the Scrip
      Awards 2009. The Biotech Company of the Year award recognizes the
      progress and achievement a biotech company has made within the last
      twelve months. The Licensing Deal of the Year award acknowledges the
      achievement of a Company in signing a licensing deal that has both
      monetary and strategic benefits to all parties. The awards ceremony
      will take place on November 18, 2009 in London.

    - In October 2009, ThromboGenics announced that it raised
      EUR0.6 million as the result of the exercise of warrants. 90.000 shares
      were created and are now listed on Euronext Brussels. As a result of
      this exercise of warrants, ThromboGenics has 26.417.789 shares
      outstanding.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB)
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 A ... accelerated partial breast irradiation (APBI) via interstitial brachytherapy ... with positive lymph nodes could be suitable to ... Oncology (ASTRO) guidelines place these patients in the ... at the 2014 ASTRO meeting, Beaumont Health System,s ...
(Date:9/17/2014)... COLUMBIA, Md. (PRWEB) September 17, 2014 ... Nexera-e Comprehensive Two-Dimensional Liquid Chromatograph (2D-LC), which ... most complex sample matrices. The system provides ... of sample analytes, which is beneficial to ... food extracts, and natural products. , Comprehensive ...
(Date:9/17/2014)... 17, 2014 Immunomic Therapeutics, Inc. announced ... (SBIR) grant to support the continued preclinical development of ... with approximately $255,000 over one year to conduct vaccine ... food allergy, affect over one million Americans and are ... Tree nut exposure is also a risk for peanut ...
(Date:9/17/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), ... technologies and products for advanced microarray diagnostics, today announced ... in the United States on ... on September 17, 2014 on the OTCQX under the ... the TSX Venture Exchange under its existing symbol SQD. ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
... Practical Implementation of ... Intra-Operative Imaging, NUREMBERG, Germany, October 13 ... at the beginning of,the year, Ziehm Imaging, provider of mobile x-ray ... provides,training in line with international standards, in order to keep its,partners ...
... SYDNEY, Australia, Oct. 13 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: ... Quarterly,Report to Shareholders on the afternoon of Wednesday ... teleconference the following morning to,review the quarter and ... on Thursday 16th October at 8.30am (Sydney),(Wednesday 15th ...
... Oct. 10 Cell Therapeutics, Inc.,(CTI) (Nasdaq and ... to,request a hearing with the NASDAQ Listing Qualifications ... NASDAQ Marketplace Rule 4450(b)(1)(A),which requires a minimum market ... a Staff Determination Letter from The NASDAQ Stock ...
Cached Biology Technology:Ziehm Imaging Extends its Training Offer 2Ziehm Imaging Extends its Training Offer 3Ziehm Imaging Extends its Training Offer 4Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 2Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 3
(Date:9/17/2014)... scientists were instrumental in the creation of the Santa ... classify the fire threat potential of the powerful, hot, ... into an inferno. The index was introduced Sept. 17 ... and San Diego Gas and Electric. , The index ... that will be used to help fire agencies and ...
(Date:9/17/2014)... (Sept. 17, 2014) A rare genetic disorder known as ... a recent joint investigation by researchers at San Diego ... In addition to suggesting better treatment options for people ... into the genetic underpinnings of autism., Jacobsen syndrome affects ... Institutes of Health. It occurs in a person when ...
(Date:9/17/2014)... IMIM (Hospital del Mar Medical Research Institute) and at ... a study in eLife showing that RNA ... evolution of new proteins, some of which could have ... proteins from the instructions found in an RNA molecule. ... containing information for the synthesis of proteins, meaning it ...
Breaking Biology News(10 mins):UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2
... video games can help to train the brain to become ... Queen Mary University of London and University College London (UCL). ... flexibility, described as a person,s ability to adapt and switch ... time to solve problems. Two groups of volunteers were ...
... drug and dietary supplement manufacturers are updating the tests used ... impurities, and the stringent new requirements, instruments and costs are ... of Chemical & Engineering News . C&EN is the ... scientific society. Ann Thayer, C&EN senior correspondent, explains that ...
... role in how people,s taste receptors send signals, leading ... Penn State food scientists. These varied, genetically influenced responses ... a range of artificial sweeteners to accommodate different consumer ... respond to tastes of foods," said John Hayes, assistant ...
Cached Biology News:Playing video games can boost brain power 2Multiple genes manage how people taste sweeteners 2
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
...
Biology Products: